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ABSTRACT 
Introduction: This study aims to assess the status of  serum vita-
min D, parathyroid hormone, type II collagen, calcium, phosphate, 
albumin, and alkaline phosphatase in osteoarthritis and rheumatoid 
arthritis patients and to study their association with rheumatoid ar-
thritis disease activity. Materials and Methods: This prospective 
cross-sectional study was conducted at the clinical analysis depart-
ment, College of  Pharmacy, Hawler Medical University in 2017. 
They study samples were collected at Rizgary Teaching Hospital 
during the period September 2015 to January 2016. A total of  
(N=156) participants were included: (N=53) patients with rheuma-
toid arthritis (RA), (N=53) with osteoarthritis (OA), and (N=50) 
healthy controls. Enzyme Linked Immuno Sorbent Assay kits de-
termined serum vitamin D, parathyroid hormone, and type II colla-
gen; and serum albumin, calcium, phosphate and alkaline phospha-
tase, were determined by standard colorimetric methods. Results 
and Discussion: Statistically significant higher levels of  parathy-
roid hormone and type II collagen, with lower levels of  Vitamin D, 
were found in the osteoarthritis group than the rheumatoid arthritis 
group and the healthy controls (P=0.007, P<0.001, P= 0.005) re-
spectively. Multiple linear regression showed a statistically signifi-
cant difference in serum type II collagen as a dependent variable, in 
patients suffering from RA or OA compared to the healthy control 
group; after adjusting for the effect of  other independent study 
variables, there was a mean increase of  (45.90 nmol/L, P<0.001) 
in RA patients, and OA patients showed greater levels of  type II 
collagen (73.950 nmol/L) than the health control group (P<0.001). 
Conclusions: Elevated type II collagen levels, in conjunction with 
a low vitamin D status, may be strong discriminator between osteo-
arthritis and rheumatoid arthritis patients.
Comparacion de biomarcadores sericos en pacientes con osteartritis y 
artritis rematoidea
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INTRODUCCTION 
Osteoarthritis (OA) and rheumatoid arthritis (RA) 
are the two most common rheumatic diseases, ac-
counting for a large percentage of  disability world-
wide. RA is an autoimmune disease of  unknown 
etiology, characterized by systemic polyarthritis that 
affects both small and large joints (1). RA occurs in 
all ethnic groups and throughout the world, with a 
female to male ratio of  3:1(2). Rheumatic disease in-
cidence increases with age, such that 56% of  those 
over 65 years will suffer from joint complaints. The 
most common type of  arthritis is OA. OA and RA 
have different etiologies; however, destruction of  
the articular cartilage is the combined feature, and 
the cause of  the typical joint dysfunction (3). 
Vitamin D plays an essential role in calcium and 
phosphate metabolism, bone formation, and miner-
alization homeostasis, and is known to play a role in 
the maintenance of  immune homeostasis, (4) reduced 
vitamin D intake has been linked to increased sus-
ceptibility to the development of  RA and found to 
be associated with disease activity in patients with 
RA (5). In OA, it is hypothesized that insufficient lev-
els of  vitamin D impact knee joint cartilage and lead 
to the development and progression of  OA of  the 
knee,(6) given the influence of  vitamin D on bone 
quality (7).
In RA, the presence of  bone erosion correlates with 
high parathyroid hormone (PTH) levels and low 
bone mineral density (BMD). These findings suggest 
that treatments to prevent bone loss or to suppress 
PTH levels might positively affect the progression 
of  bone erosion in RA (8). In patients with OA, PTH 
has an inhibiting role regarding terminal differenti-
ation of  chondrocytes and in turn, suppresses OA 
progression (9,10).
Cartilage destruction is a crucial aspect of  both types 
of  arthritis and is characterized by the degradation 
of  cartilage proteins, proteoglycans, and type II col-
lagen, which are embedded within the extracellular 
matrix. Degradation of  type II collagen results in ir-
reversible damage and appears to be a candidate as a 
marker of  cartilage degradation and disease activity 
in arthritis (11). The aim of  the study is to evaluate 
the status of  vitamin D, parathyroid hormone, type 
II collagen, calcium, phosphate, albumin, and alka-
line phosphatase in patients with OA and RA, and to 
study their association with RA disease activity.
MATERIALS AND METHOD
Study Groups: This was a prospective cross-sec-
tional study comprising (50) healthy volunteers indi-
viduals were chosen randomly; these had no history 
or clinical sign and symptoms of  RA and OA, and 
were aged 21 to 74 years, both genders were included 
and 106 patients: 53 patients with OA, and 53 with 
RA. Disease Activity Scores (DAS 28) were assessed 
for all RA patients by a specialist, Disease Activity 
Score 28 (DAS 28) involved calculating number of  
tender and swollen joint in 28 joints includes shoul-
ders, elbows, wrists, knee, small joints of  hands 
(metacarpophalangeal (MCP) joints, interphalangeal 
(PIP) joints, interphalangeal (IP) joints of  thumps), 
visual analogue scale (VAS) and ESR or CRP.
All patients were aged between 21 to 75 years, and 
both genders were included. The participants were 
patients who were admitted to, or received consul-
tations at, Rizgary Teaching Hospital between Sep-
tember 2015 and January 2016, and who agreed to 
complete a questionnaire on disease manifestations. 
All participants were diagnosed and evaluated by 
a specialist in the Rheumatology department, who 
used American College of  Rheumatology criteria 
(2010) (12).  The study was approved by the Ethics 
Committee of  the College of  Pharmacy, Hawler 
Medical University, and participants consent was ob-
tained in verbal form. 
Sample Collection: Eight milliliters (mls) of  venous 
blood were collected, without tourniquet, from each 
subject. The blood was allowed to clot, and centri-
fuged for 15 minutes at 3000 rounds per minute. The 
resultant obtained sera were dispensed into four ep-
pendorf  tubes and immediately frozen at -20 °C till 
the time of  assay. 
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Exclusion Criteria: Patients suffering from liver 
diseases and renal diseases; Systemic Lupus Erythe-
matosus (SLE); hyperparathyroidism; and hypopara-
thyroidism; as well as those who had undergone joint 
replacement; and those receiving estrogen therapy, 
or calcium, vitamin D or glucose amine supplemen-
tation, were excluded.  
Study Protocol: A detailed history from both pa-
tient groups (RA and OA) and the HC group, were 
taken and monitoring of  disease activity for RA pa-
tients, using DAS 28, was performed. 
Statistical Analysis: Statistical analyses were per-
formed using SPSS (Statistical Package for Social 
Sciences) version 21-computer software, in addition 
to special formulas developed using Microsoft Excel 
2016. 
Analysis of  Variance (ANOVA) was used to test 
the statistical significance of  differences in mean of  
a normally distributed variable between more than 
two groups. Further exploration of  the statistical sig-
nificance of  the difference in mean between all pos-
sible paired combinations of  groups was explored by 
a least significant difference test (LSD) (13). ‘P’ value 
of  ≤ 0.05 was considered as statistically significant.
RESULTS 
The results were based on analysis of  study biomark-
ers for 53 OA patients and 53 RA patients (N=106), 
and (N=50) healthy controls. Study biomarkers were 
evaluated for their relationship to RA disease ac-
tivity. As shown in table 1, a statistically significant 
differences were observed in mean age between the 
studied groups. This (mean ± SD) was significantly 
higher in OA patients compared to both the HC and 
RA groups, at (56.6 ± 10.3) years, (47 ±13.7) years, 
and (45.8 ± 13.3) years respectively, with P< 0.001. 
The difference in mean age failed to reach statistical 
significance between the RA and HC groups, with a 
P value = 0.61. The mean BMI showed a statistically 
significant difference, and was higher (31.2 ± 4.7Kg/
m2) in the OA group, compared to the HC and RA 
groups (28.2 ± 5.1 Kg/m2) and (26.6 ± 5.3 Kg/m2) 
respectively, with a significance of  P< 0.001. 
Table 1: Differences in (mean ± SD) age and Body Mass Index between the studied groups.
Study variables HC N =50 
OA 
N=53 
RA 
N=53 P (t-test) 
Age (years)     < 0.001 
 
Mean ± SD 47±13.7 56.6±10.3 45.8±13.3 
 
P (LSD) for difference in mean between::
     
Rheumatoid arthritis and Healthy controls
    
0.61 [NS]
 
Rheumatoid arthritis and Osteoarthritis
    
<0.001
 
Osteoarthritis x Healthy controls
    
<0.001
 
Body Mass Index (kg/m2)
    
<0.001
 
Mean ± SD 28.2±5.1 31.2±4.7 26.6±5.3
P (LSD) for difference in mean between
Rheumatoid arthritis x Healthy controls    0.11[NS] 
Rheumatoid arthritis x Osteoarthritis    <0.001 
Osteoarthritis x Healthy controls    0.002 
NS: not significant
A statistically significant difference was observed in 
the mean of  vitamin D across the study groups. This 
was shown to be higher in the HC group (24.75 ± 
16.58 ng/ml) compared to the RA and OA groups, 
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for which the means were (14.84 ± 12.74 ng/ml) and 
(9.31 ± 7.79 ng/ml) respectively with a P value = 
0.005. The difference in the mean also reached sta-
tistical significance when comparing the HC and RA 
groups, with a P value = 0.007; between the RA and 
OA groups, with a P value = 0.003; and between the 
HC and OA groups, with a P value = 0.008 (table 2).
A highly statistically significant difference was ob-
served in the mean of  PTH between the groups. 
This was shown to be higher in the OA group (39.56 
± 28.08 Pg/ml) than in the RA group (26.67 ± 15.49 
Pg/ml) and HC group (25.53 ± 15.84 Pg/ml) re-
spectively, with a P value<0.001. There was no sta-
tistically significant difference between the RA and 
HC groups in this regard, with a P value = 0.78 (see 
table 2).
Similarly, the mean for serum type II collagen was 
statistically higher in the OA group (190 ± 5.1 nmo-
l/L) compared to the RA and HC groups, for which 
the mean was (162 ± 5.1 nmol/L) and (116 ± 4.1 
nmol/L) respectively, with a P value < 0.001. The 
differences in mean also reached statistical signifi-
cance when comparing the RA and HC groups in 
this regard, with a P value <0.001 (see table 2).
 
Table 2: Differences in mean of  selected serum parameters between the groups.
Study variables HCN = 50  
OA
N = 53  
RA
N = 53  P(T-test) 
Vitamin D (ng/ml)    0.005 
Mean ± SD 24.75 ± 16.58 9.31 ± 7.79 14.84 ± 12.74  
P (LSD) for difference in mean between:
    Healthy controls and rheumatoid arthritis
   
0.007
 Rheumatoid arthritis and Osteoarthritis
   
0.003
 
Healthy controls and Osteoarthritis
    
0.008
 
Parathyroid hormone (Pg/ml)
    
<0.001
 
Mean± SD
 
25.53 ± 15.84 39.56 ± 28.08 26.67 ± 15.49 
 
P (LSD) for difference in mean between:
     
Rheumatoid arthritis and healthy controls
    
0.78[NS]
 
Rheumatoid arthritis and Osteoarthritis
    
0.002
 
Osteoarthritis and healthy controls
    
<0.001
 
Type II collagen (nmol/L)
    
<0.001
 
Mean± SD
 
116±4.1
 
190±5.1
 
162±5.1
  
P (LSD) for difference in mean between:
Rheumatoid arthritis and healthy controls <0.001
Rheumatoid arthritis and Osteoarthritis <0.001
Osteoarthritis and healthy controls <0.001
NS: not significant
Regarding the other study biomarkers, alkaline phos-
phatase (ALP) showed a significantly higher mean in 
the OA group (8.51 ± 4.07 KAU/dl) compared to 
the RA group (3.68 ± 2.61 KAU/dl) and HC groups 
(4.78 ± 3.91 KAU/dl), with a P value < 0.001 (see ta-
ble 3). The presence of  statistically significant higher 
mean serum total calcium, free calcium, phosphate, 
and albumin were detected in the HC group than the 
RA and OA groups. The mean value for free calcium 
in the HC group was (5.13 ± 0.27 mg/dl), for the RA 
group (4.89 ± 0.18 mg/ml), and for the OA group 
(4.75 ± 0.37 mg/dl), with a P value < 0.00) (see table 
3). The mean values for serum phosphate were, for 
the HC group (5.55 ± 1.52 mg/dl), the OA group 
(5.43 ± 1.15 mg/dl), and the RA group (4.3 ± 2.25 
mg/dl), with a P value < 0.001. A similar finding was 
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observed for serum albumin: the mean for the HC 
group was (4.87 ± 0.66 g/dl), (4.5 ± 0.46 g/dl) for 
the OA group, and (4.73 ± 0.78 g/dl) for the RA 
group, with a P value of  0.015 (see table 3).
Table 3: Differences in mean of  selected serum biomarkers between the groups.
Study variables HC N=50 
OA 
N=53 
RA 
N=53 P(t-test) 
Alkaline phosphatase (KAU/dl)    <0.001 
Mean ± SD 4.78 ± 3.91 8.51 ± 4.07 3.68 ± 2.61  
Calcium (mg/dl)    <0.001 
Mean ± SD 9.97±1.06 8.56±1.34 9.05±0.65  
Free calcium (mg/dl)    <0.001 
Mean ± SD 5.13±0.27 4.75±0.37 4.89±0.18  
Phosphate (mg/dl)    < 0.001 
Mean ± SD 5.55±1.52 5.43±1.15 4.3±2.25  
Albumin (g/dl)    0.015 
Mean ± SD 4.87±0.66 4.45±0.46 4.73±0.78  
 
No significant difference was observed in terms of  mean age and BMI, relating to either type of  disease 
activity (moderate activity and high activity) (see table 4).
Table 4: Differences in mean age and Body Mass Index (BMI) between those with moderate dis-
ease activity and those with high disease activity in the RA group.
RA disease activity
 
   
 
 
Study variables Moderate activityN=18
High activity
N=35 P(t-test) 
Age (years)   0.17[NS] 
Mean ± SD 42.3±14.4 47.5±12.5  
Body Mass Index (Kg/m2)   0.89[NS] 
Mean ± SD 26.4±5.4 26.7±5.3  
 
[NS]: not significant
Only type II collagen showed a statistically signifi-
cant difference between the two disease score activ-
ity levels; the mean was higher for moderate activity 
(164.1 ± 5.2 nmol/L) than high activity (160.9 ± 4.8 
nmol/L), with 
a P value = 0.03. The other studied biomarkers (vita-
min D, PTH) showed no statistically significant dif-
ferences. (Table 5) in this regard. 
 
6
ISSN: 2346-075X Bucaramanga - Colombia
Table 5: Differences in mean of  selected serum parameters between those with moderate disease 
activity and those with high disease activity in the RA group.
RA disease activity
 
Study variables Moderate activity N = 18 
High activity 
N = 35 P(t-test) 
Vitamin D (ng/ml)   0.4 [NS] 
Mean ± SD 16.9 ± 19.5 13.78 ± 7.39  
Parathyroid hormone (pg/ml)   0.08[NS] 
Mean ± SD 21.49±14.99 29.34±15.27  
Type II collagen (nmol/L)   0.03 
Mean ± SD 164.1 ± 5.2 160.9 ± 4.8  
 
[NS]: not significant
None of  the other studied biomarkers (ALP, total calcium, free calcium, phosphate, and albumin) showed 
statistically significant differences in terms of  disease activity scores (see table 6).
Table 6: Differences in mean of  selected serum biomarkers between those with moderate disease 
activity and those with high disease activity in the RA group.
RA disease activity 
Study variables Moderate activity N = 18 
High activity 
N = 35 P(t-test) 
Alkaline phosphatase (KAU/dl)   0.21[NS] 
Mean ± SD 3.04 ± 2.22 4.01 ± 2.77  
Calcium (mg/dl)   0.31[NS] 
Mean ± SD 8.92±0.57 9.11±0.69  
Free calcium (mg/dl)   0.31[NS] 
Mean ± SD 4.86±0.16 4.91±0.18  
Phosphate (mg/dl)   0.25[NS] 
Mean ± SD 3.81±1.76 4.56±2.45  
Albumin (g/dl)   0.36[NS] 
Mean ± SD 4.87±0.78 4.66±0.77  
 
[NS]: not significant
A statistically significant change in serum type II 
collagen was detected when the patient was in the 
RA, as compared to the HC, group: after adjusting 
for the effect of  other independent variables (their 
effect fixed to zero), there was a mean increase of  
(45.90 nmol/L, P<0.001). Patients with OA were 
seen to have more serum type II collagen at (73.950 
nmol/L) than the HC group, with a significance of  
P<0.001; while the independent variables of: pre-
vious fracture, steroidal treatment, non-steroidal 
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anti-inflammatory treatment, being a smoker, BMI, 
age, male gender compared to female) were seen to 
have no significant effect on serum type II collagen, 
the dependent variable is type II collagen (see table 
7).
Table 7: Multiple linear regression model with type II collagen (nmol/L) as the dependent (re-
sponse) variable; the role of  RA and OA compared to healthy controls (HCs); and with selected 
confounders as explanatory (independent) variables.
Type II collagen (nmol/L) Partial regression coefficient P value 
Standardized 
coefficients 
RA group, compared to healthy controls 45.906 <0.001 0.700 
OA group, compared to healthy controls 73.950 <0.001 1.138 
Previous fracture -0.126 0.24[NS] -0.016 
Steroidal treatment 0.226 0.86[NS] 0.003 
Non-steroidal treatment
 
0.720 0.53[NS] 0.008 
Being a smoker -0.417 0.73[NS] -0.005 
Body Mass Index (kg/m2)
 
-0.075 0.37[NS] -0.013 
Age (years)
 
0.040 0.24[NS] 0.017 
male gender compared to female
 
0.744 0.46[NS] 0.011 
 
R2=0.977
P (Model) <0.001
DISCUSSION 
Vitamin D in Study Groups.
Observations provide a rationale for the measure-
ment of  serum vitamin D (25(OH) D) in patients 
with OA and the encouragement of  supplementa-
tion to raise the serum concentration to adequate 
levels. It is suggested that serum vitamin D measure-
ment should be considered in any patient with symp-
toms suggestive of  OA, even before the appearance 
of  radiographic changes (14). This study showed that 
healthy controls have higher serum vitamin D values 
than RA and OA groups; this corroborates the litera-
ture (15) that shows RA patients have lower vitamin D 
values than healthy controls. Even though the defi-
nition of  normal vitamin D plasma concentration is 
still debated, a classification of  vitamin D status on 
which many would agree is: deficiency 25(OH) D 
<20 ng/mL, insufficiency 20 – 30 ng/mL, normality 
>30 ng/m.16 
The differences between study groups are signifi-
cant, but the mean values in the study groups are 
at insufficient and deficient levels: the majority of  
patients with OA showed vitamin D deficiency. This 
may be reflective of  endemic vitamin D deficiency 
in Iraqi people, which could be attributed to cultural 
practices such as clothing. Though Iraq is a very sun-
ny country, with strong sunshine most of  the year, 
most people wear long garments and the women 
usually cover their heads. Therefore, exposure to the 
sun is low, negatively impacting vitamin D levels.
Vitamin D deficiency in OA patients in this study 
are consistent with previous reports, (17,18) and adds 
new information to the current knowledge base. The 
finding that the healthy control group also had se-
rum vitamin D insufficiency is attributed to lack of  
exposure to the sun, though the presence of  asymp-
tomatic OA in the control group cannot be ignored. 
Since the performing of  radiographic examination 
in the asymptomatic controls was not clinically indi-
cated, this potential study limitation should be tak-
en into account. This issue could have lowered the 
mean serum vitamin D level in the control group 
and reduced the mean difference between the patient 
and control groups.
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Although this was not a longitudinal study, the data 
demonstrated deficiency in vitamin D in the OA 
group associated with significantly low bone meta-
bolic markers (serum, calcium, and phosphate) (table 
3). This suggests an association between these mark-
ers and supports the idea that raising serum vitamin 
D to sufficient levels may exert beneficial effects in 
patients with knee OA, as well as the potential of  vi-
tamin D treatment in suppression of  turnover mark-
ers (19).
Higher BMI values (greater than 30 kg/m2) have 
been shown to be associated with low vitamin D (20) 
and the current study is in agreement with this find-
ing. Patients with OA are seen to have a higher BMI 
(31 kg/m2), associated with low vitamin D (Table 1). 
Obese patients may have low serum vitamin D levels 
due to the decreased passage of  vitamin D from skin 
to the general circulation.
Our study showed no significant correlation in se-
rum vitamin D and disease activity in RA patients, 
this may be due to the small sample size of  the RA 
subgroups (Table 5), this finding is agree with pre-
vious researches. (21,15) however, is contrary to some 
research, (22,23) which shows vitamin D levels cor-
relate inversely with RA activity. Another study also 
showed decreased serum vitamin D levels in active 
RA, than in the ‘moderate activity’ group. (24) 
Parathyroid Hormone in Study Groups.
It is well known that vitamin D influence on bone is 
tightly linked to PTH activity. Vitamin D requires the 
presence of  PTH to act on bone, and it down-regu-
lates PTH synthesis both indirectly (through increas-
ing calcium concentration) and directly (through ac-
tivating Vitamin D Responsive Elements – VDRE) 
in the promoting of  the PTH gene. Vitamin D also 
inhibits parathyroid cells’ proliferation(25) and modu-
lates sensitivity to calcium, increasing the transcrip-
tion of  CaSR (Calcium Sensing Receptor) (26).  These 
molecular pathways have an important clinical impli-
cations, even though in the last decade other bone 
health determinants have been used to define vita-
min D status. The definition of  normal plasma vi-
tamin D concentration is mainly based on the iden-
tification of  the level able to suppress PTH. This 
threshold of  normality has been set by some at 30 
ng/mL (75 nmoL/L) (27). 
Given the above – a vitamin D at 30 ng/ml con-
centration able to control and suppress PTH – this 
molecular pathway indicates that, vitamin D below 
this level may lose its ability to control PTH, this 
effective link clearly demonstrated in our study re-
sults, however, the mean vit D below 30ng/ml in all 
study groups kept PTH within normal level as well 
as bone biomarkers (calcium, phosphate, and ALP), 
thus in deficiency of  vitamin D, PTH act as a glob-
al biomarker for the maintenance of  serum calcium 
directly and phosphate indirectly but such condition 
enhances demineralization of  the bone particularly 
in the OA group. 
Type II Collagen in Study Groups.
The present study demonstrated a highly significant 
increase in serum type II collagen and PTH in the 
OA group. This is associated with severe vitamin D 
deficiency, with many potential consequences. One 
of  the possible explanations for the results found in 
this study is the role of  vitamin D on the cartilage 
degeneration marker type II collagen. A recent study 
(28) showed that vitamin D deficiency can directly in-
hibit the expression of  multiple proteins in articular 
cartilage, such as Transforming Growth Factor– β1 
(TGF–β1), Matrix Metalloproteinase-9 (MMP – 9), 
and Matrix Metalloproteinase-13 (MMP – 13), lead-
ing to cartilage degradation. In the absence of  dra-
matic changes in mechanical loading, such as trau-
matic surgery, the mechanism above might be the 
main cause of  induced OA in the early stages of  vi-
tamin D deficiency, which might prove another po-
tential factor involved, in particular, in OA. Further-
more, this confirms the protective role of  vitamin D 
on articular cartilage. The protective effects of  vita-
min D supplementation on knee OA were observed 
in the same study (28). 
PTH also has an important role in collagen metab-
olism. One study showed the ability of  PTH to in-
hibit the expression of  COL X (an anabolic marker) 
while promoting the expression of  type II collagen 
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(a catabolic marker), thereby preventing endochon-
dral ossification. (29) This demonstrated high serum 
level of  type II collagen in OA patients  compared 
to healthy controls and RA patients, indicating that 
the rate of  type II collagen degradation is increased 
in OA.This finding corroborates previous studies 
which demonstrated an increase in type II collagen 
breakdown products in urine, (30, 31) and cartilage ex-
plants; (32) it is also consistent with the results of  the 
current study, in regard to the combination of  vita-
min D deficiency and high PTH generating a signif-
icant increase in type II collagen in the OA group. 
The multiple linear regression model with type II 
collagen showed that collagen is the potential dis-
criminatory biomarker between the studied groups, 
with R2=0.977, P <0.001.
CONCLUSIONS
The study found that vitamin D deficiency is quite 
common in RA and OA patients, with insufficien-
cy in the healthy control group. This issue may have 
been overlooked as a health problem in this region, 
but it is not uncommon in sunny countries. The 
presence of  significantly high PTH and bone bio-
markers (calcium, phosphate, and ALP), in the OA 
group appears to show the significant role of  vi-
tamin D deficiency. PTH plays a major role in the 
maintenance of  serum bone biomarkers (calcium, 
phosphate, and ALP), within normal range, across 
all study groups, especially in OA. Type II Collagen 
is a potential discriminator between healthy subjects 
and those suffering from osteoarthritis or rheuma-
toid arthritis. Amoge study biomarkers only Type II 
Collagen showed significantly high in moderate RA 
disease activity.
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